[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355344-105":59,"doc-detail-355344-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","research-advances-on-targets-and-mechanisms-in-cancers-complicated-by-cardiovascular-diseases","Research Advances on Targets and Mechanisms in Cancers Complicated by Cardiovascular Diseases","","Cancers complicated by cardiovascular diseases (CVDs) increasingly limit long-term quality of life and clinical outcomes, making systematic identification of therapeutic targets essential. A target-based analytical framework was built by analyzing clinical trial data for tumors co-occurring with CVDs across target distribution, developmental stage, maturity, and mechanistic relevance. Among 58 trials, 45 therapeutic targets were identified, with coagulation-related targets and SERPINC1 highlighted as high-frequency core targets.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/research-advances-on-targets-and-mechanisms-in-cancers-complicated-by-cardiovascular-diseases/355344/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/research-advances-on-targets-and-mechanisms-in-cancers-complicated-by-cardiovascular-diseases/355344.png","ImageObject",300,407,{"name":92,"@type":93},"\tJames","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of the study?","Question",{"text":112,"@type":113},"To establish a target-based framework that maps the distribution, developmental stage, maturity, and mechanisms of clinical trials involving tumors co-occurring with CVDs, and to identify potential therapeutic targets.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many clinical trials and therapeutic targets were included?",{"text":117,"@type":113},"The analysis included 58 clinical trials and identified 45 therapeutic targets.",{"name":119,"@type":110,"acceptedAnswer":120},"Which therapeutic targets were highlighted as high-frequency core targets?",{"text":121,"@type":113},"Coagulation Factor X, thrombin, and SERPINC1 were reported as high-frequency core targets.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355344,1790818444,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","OncoTargets and Therapy  \n Open Access Full Text Article  \nREVIEW  \nResearch Advances on Targets and Mechanisms in Cancers Complicated by Cardiovascular Diseases  \nJianing Li 1 , Peili Wang2  \n1Graduate School, Heilongjiang University of Chinese Medicine, Harbin, People’s Republic of China; 2Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of China  \nCorrespondence: Peili Wang, Email [191593690@qq.com](191593690@qq.com)  \n\n| Purpose: Cancers complicated by cardiovascular diseases (CVDs) are increasingly becoming major limiting factors affecting patients’ long-term quality of life and clinical outcomes. Systematic identification of therapeutic targets and their clinical development status is crucial for optimizing treatment strategies. Therefore, this study aimed to establish a target-based analytical framework to systematically map the distribution, developmental stage, maturity, and mechanistic characteristics of clinical trials investigating tumors co-occurring with CVD, thereby identifying potential therapeutic targets.\u003Cbr>Patients and Methods: We analyzed clinical trial data on treatments for cancers complicated by CVDs. A total of 58 clinical trials were included and examined across multiple dimensions, including target distribution, development stage, and disease relevance. Results: Forty-five therapeutic targets were identified, with coagulation Factor X, thrombin, and serpin family C member 1 (SERPINC1) emerging as high-frequency core targets. Most studies focused on coagulation, inflammation, and endothelial pathways. Significant variations were observed in completion status and research phase across different targets, with some demonstrating dual therapeutic and cardiovascular regulatory potentials.\u003Cbr>Conclusion: Coagulation and endothelium-related targets emerged as key links between cancer progression and cardiovascular complications. SERPINC1 and 3-hydroxy-3-methylglutaryl-CoA reductase showed potential for synergistic therapy. This study provides a comprehensive overview of targeted therapies for tumors with concomitant CVD, revealing key pathways and underexplored mechanisms. It offers data-driven insights and directional guidance for precision treatment design.\u003Cbr>Keywords: cardiovascular disease, therapeutic target, cancer, clinical trial, cardiovascular complication |\n| --- |\n| Introduction\u003Cbr>The overall survival rate of patients with cancer has recently improved with continuous advancements in early screening technology for tumors and the widespread application of diverse treatment strategies.1 However, the extending lifespan also introduces new challenges. For example, cardiovascular toxicity resulting from anti-tumor therapy and cancerinduced cardiovascular complications are increasingly becoming key limiting factors that affect patients’ long-term quality of life and clinical outcomes.2 Epidemiological evidence indicates that cardiovascular disease has become one of the leading non-cancer causes of morbidity and mortality among cancer survivors. According to estimates, up to 20%– 30% of patients with cancer may develop cardiovascular complications, including cardiomyopathy, arrhythmia, and ischemic heart disease.3 Moreover, venous thromboembolism (VTE) represents the second leading cause of death inpatients with cancer after cancer itself. VTE necessitates long-term anticoagulant therapy, carries an annual risk of bleeding complications at 12%, and presents a substantial annual recurrence risk of 21% even with anticoagulation treatment.4\u003Cbr>Anti-tumor medications can cause damage to the cardiovascular system through various mechanisms. For example, anthracycline drugs can cause dose-dependent myocardial injury and reduced ejection fraction; human epidermal growth factor receptor 2 (HER2) inhibitors may lead to myocardial dysfunction by inhibiting the HER2 signaling pathway, disrupting mitochondrial function, and inducing oxidative stress in cardiomyocytes; and vascu","cbCaikQzG0HN4jbU","https://ap.wps.com/l/cbCaikQzG0HN4jbU","pdf",3452238,14,"English","# Introduction\n## Purpose and target-based analytical framework\n# Patients and Methods\n## Clinical trial data analysis\n# Results\n## Therapeutic target identification\n## Pathway focus and target variation\n# Conclusion\n## Coagulation and endothelium-related mechanisms","[{\"question\":\"What is the main purpose of the study?\",\"answer\":\"To establish a target-based framework that maps the distribution, developmental stage, maturity, and mechanisms of clinical trials involving tumors co-occurring with CVDs, and to identify potential therapeutic targets.\"},{\"question\":\"How many clinical trials and therapeutic targets were included?\",\"answer\":\"The analysis included 58 clinical trials and identified 45 therapeutic targets.\"},{\"question\":\"Which therapeutic targets were highlighted as high-frequency core targets?\",\"answer\":\"Coagulation Factor X, thrombin, and SERPINC1 were reported as high-frequency core targets.\"}]","Research Advances on Targets and Mechanisms in Cancers Complicated by Cardiovascular Diseases | PDF",1790117939,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3c7166278f6804b04d76f3532d35c47.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b27ca6759296effc42d06a11e3a2fd6.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19a965e0283a0eb0d7e3b4ad9164cb65.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24aedcbad3850fe887ae0b2825797a3f.webp",980,1268]